Multidimensional Evaluation of 7 Kinds of Injectable Brain Cytoprotection Agents for Ischemic Stroke
10.3870/j.issn.1004-0781.2025.05.017
- VernacularTitle:7种注射剂型脑细胞保护剂治疗缺血性脑卒中的临床综合评价
- Author:
Anhua WEI
1
;
Lu WANG
1
;
Lu ZENG
1
;
Dong LIU
1
;
Xuepeng GONG
1
Author Information
1. 华中科技大学同济医学院附属同济医院药学部,武汉 430030
- Publication Type:Journal Article
- Keywords:
Brain cytoprotection agents;
Ischemic stroke;
Drug evaluation;
Drug selection
- From:
Herald of Medicine
2025;44(5):778-786
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct a multidimensional evaluation of brain cytoprotection agents used in the treatment of ischemic stroke,and to provide an evidence-based basis of medication selection and rational clinical use for medical institutions'decision-makers.Methods Based on the"Quick Guide to Drug Evaluation and Selection for Chinese Medical Institutions(Second Edition)"evaluation system,some scoring rules were adjusted.Referring to drug instructions,clinical guidelines,and rel-evant literature from databases such as China National Knowledge Infrastructure(CNKI),Wanfang Database,VIP Database for Chinese Technical Periodicals(VIP),Pubmed,Embase,and Cochrane Library,seven brain cytoprotection agents were quantita-tively scored from five dimensions:pharmacological characteristics,effectiveness,safety,economic aspects,and other attributes(insurance coverage,essential drugs,manufacturing enterprises).Results Overall,the evaluated drugs received low scores.The top three drugs were edaravone and dexborneol injection(63.15 points),urinary kallidinogenase injection(62.20 points),and butylphthalide injection(62.04 points).Citicoline injection had the lowest score due to unclear effectiveness(37.07 points).Conclusions Based on guideline recommendations,edaravone and dexborneol,urinary kallidinogenase,and butylphthalide,which scored above 60,are weakly recommended when no alternative medications are available in medical institutions.This study can be used as a reference for the selection of therapeutic drugs for ischemic stroke in medical institutions and offer a basis for rational clinical medication use.
